Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects

NCT02042001 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Impaired Cognition
Depression/Anxiety
Poor Quality Sleep
Quality of Life
HIV-1 Infection

Interventions

DRUG: Immediate switch to TDF/FTC/RPV
DRUG: Switch to TDF/FTC/RPV after 24 weeks

Sponsor

Azienda Ospedaliera San Gerardo di Monza

Collaborators

[object Object]